Pharmaceutical News Wrap Up: January 2014

The pharmaceutical lawyers at the Firm are committed to keeping you up-to-date on the latest pharmaceutical news. Below is a short list of some of the most recent headlines concerning FDA recalls, approvals and warning label changes, medical studies and other pharmaceutical news taking place across the country and world.

  • Merck Recalling Drug Combination for Cholesterol
    Pharmaceutical giant Merck announced it was recalling its drug Liptruzet, a combination cholesterol drug, due to defects in the packaging which could reduce the drug’s effectiveness. The recall will wipe out the entire stock of Liptruzet in the United States. Liptruzet is a combination of ezetimibe and atorvastatin. Atorvastatin is the generic name for Lipitor.
  • Testosterone Testing, Treatment Soars Despite Uncertainties
    Rate of testosterone testing and the use of low T treatments have been sky-rocketing in the United States and United Kingdom. While testosterone testing is higher in the U.K., supplementation with testosterone therapy is less frequent in the U.K. compared to the United States.
  • FDA Warns Against High-dose Prescription Acetaminophen
    The Food & Drug Administration is asking medical practitioners to stop prescribing medications that contain more than 325 milligrams of acetaminophen because of the risk of liver damage. It also plans to withdraw approval for any medications in the coming months that still contain more than 325 mg of acetaminophen.
Simmons Support Team
Simmons Hanly ConroyWritten by:

Editorial Team

The Simmons Hanly Conroy Editorial Team consists of journalists, writers and editors who strive to deliver accurate and useful information to families needing legal help. Our team works alongside the firm's attorneys and partners, as well as with medical professionals and other specialists, to keep all information relevant and helpful.